Seven Grand Managers LLC Purchases Shares of 25,000 Nuvalent, Inc. $NUVL

Seven Grand Managers LLC purchased a new stake in shares of Nuvalent, Inc. (NASDAQ:NUVL) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 25,000 shares of the company’s stock, valued at approximately $2,515,000.

Several other institutional investors have also added to or reduced their stakes in NUVL. GAMMA Investing LLC boosted its position in Nuvalent by 47.6% during the fourth quarter. GAMMA Investing LLC now owns 335 shares of the company’s stock valued at $34,000 after buying an additional 108 shares during the period. Aster Capital Management DIFC Ltd purchased a new stake in Nuvalent during the third quarter valued at about $38,000. NBC Securities Inc. purchased a new stake in Nuvalent during the fourth quarter valued at about $125,000. KBC Group NV boosted its position in Nuvalent by 24.1% during the fourth quarter. KBC Group NV now owns 1,527 shares of the company’s stock valued at $154,000 after buying an additional 297 shares during the period. Finally, Compass Wealth Management LLC purchased a new stake in Nuvalent during the third quarter valued at about $172,000. 97.26% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, insider Deborah Ann Miller sold 5,500 shares of the company’s stock in a transaction dated Thursday, April 30th. The shares were sold at an average price of $99.22, for a total transaction of $545,710.00. Following the completion of the transaction, the insider directly owned 59,634 shares of the company’s stock, valued at approximately $5,916,885.48. This represents a 8.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Henry E. Pelish sold 3,093 shares of the company’s stock in a transaction dated Thursday, April 9th. The shares were sold at an average price of $104.48, for a total transaction of $323,156.64. Following the transaction, the insider directly owned 65,604 shares of the company’s stock, valued at approximately $6,854,305.92. This trade represents a 4.50% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 80,023 shares of company stock valued at $8,235,217. 5.02% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research firms have issued reports on NUVL. Weiss Ratings restated a “sell (d-)” rating on shares of Nuvalent in a research report on Tuesday, April 21st. HC Wainwright restated a “buy” rating and set a $155.00 price target on shares of Nuvalent in a research report on Tuesday, April 21st. Sanford C. Bernstein began coverage on shares of Nuvalent in a research report on Thursday, May 21st. They set an “outperform” rating and a $189.00 price target for the company. Wedbush restated an “outperform” rating and set a $125.00 price target on shares of Nuvalent in a research report on Wednesday, April 8th. Finally, Wells Fargo & Company started coverage on shares of Nuvalent in a research report on Monday, March 30th. They set an “overweight” rating and a $116.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $140.29.

Nuvalent Trading Up 2.3%

Shares of NASDAQ:NUVL opened at $107.38 on Thursday. The company has a market cap of $8.48 billion, a price-to-earnings ratio of -17.72 and a beta of 1.15. The company has a 50-day moving average price of $102.56 and a 200-day moving average price of $103.08. Nuvalent, Inc. has a 12 month low of $70.25 and a 12 month high of $113.01.

Nuvalent (NASDAQ:NUVL) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($1.35) by ($0.04). During the same quarter in the previous year, the company earned ($1.18) EPS. As a group, research analysts forecast that Nuvalent, Inc. will post -5.74 EPS for the current fiscal year.

Nuvalent Profile

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.